Drug Trial Radar · NCT05918302
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Oct 27, 2023
Primary completion
Mar 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Lumara Bio Oncologics GmbH; MFAR
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.
Conditions
- Neuroendocrine Tumors
- Lung Neuroendocrine Neoplasm
- Thymus Neoplasms
Interventions
177Lu-edotreotideDrug
6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
EverolimusDrug
10 mg orally once daily (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Throughout the study period, approximately 3 years per patient
Locations
27 sites in 4 countries. Site status is shown where the registry gives one.
UCL Saint-Luc
Brussels, Belgium · Recruiting
CHU Liège
Liège, Belgium · Recruiting
Antwerp University Hospital (UZA)
Edegem, Edegem, Belgium · Recruiting
Centre Hospitalier Universitaire (CHU) Bordeux
Bourdeaux, France · Recruiting
Lille University Hospital
Lille, France · Recruiting
Hôpital Edouard Herriot, Lyon
Lyon, France · Recruiting
Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, France
Marseille, France · Recruiting
Department of Digestive Oncology, CHU Saint Eloi, Montpellier, France/ ICM Cancer Institute at Montpellier
Montpellier, France · Recruiting
Centre Hospitalier Universitaire de Nantes
Nantes, France · Recruiting
I. Gustave Roussy, Paris
Paris, France · Recruiting
Hospital Center University Dijon Bourgogne (CHU Bourgogne)
Dijon, Dijon, France · Recruiting
AOU Consorziale Policlinico di Bari - CROB Referrall Cancer Center of Basilicata
Bari, Italy · Recruiting
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Irsì - Meldola
Meldola, Italy · Recruiting
Istituto Europeo di Oncologia - Milano
Milan, Italy · Recruiting
Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence Rome, Rome, Italy.
Roma, Italy · Not yet recruiting
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy · Recruiting
Azienda USL IRCCS Di Reggio Emilia
Reggio Emilia, Reggio Emilia, Italy · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Virgen del Rocío
Seville, Andalusia, Spain · Recruiting
ICO Institut Català d'Oncologia L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Complexo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, Galicia, Spain · Recruiting
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain · Recruiting
Hospital Universitario Ramón y Cajal, Madrid
Madrid, Madrid, Spain · Recruiting
Fundación Jiménez Díaz University Hospital
Madrid, Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain · Recruiting
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain · Recruiting
Hospital Universitario y Politécnico La Fe
Valencia, Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.